SPX Gestao de Recursos Ltda Acquires Shares of 5,400 Natera, Inc. $NTRA

SPX Gestao de Recursos Ltda acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 5,400 shares of the medical research company's stock, valued at approximately $1,466,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Horizon Investments LLC raised its holdings in shares of Natera by 22.0% during the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company's stock valued at $56,000 after buying an additional 44 shares during the period. Parallel Advisors LLC lifted its position in Natera by 5.5% during the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company's stock worth $181,000 after acquiring an additional 47 shares in the last quarter. First Horizon Corp boosted its holdings in Natera by 5.5% in the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company's stock worth $196,000 after acquiring an additional 51 shares during the period. Siemens Fonds Invest GmbH boosted its holdings in Natera by 3.1% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company's stock worth $290,000 after acquiring an additional 54 shares during the period. Finally, Alamea Verwaltungs GmbH grew its position in Natera by 2.9% in the fourth quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company's stock valued at $515,000 after acquiring an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Guggenheim lifted their price objective on shares of Natera from $290.00 to $360.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. BTIG Research upped their target price on shares of Natera from $290.00 to $320.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Evercore reaffirmed an "outperform" rating and set a $300.00 price target on shares of Natera in a report on Monday, July 6th. Stephens lifted their price target on shares of Natera from $305.00 to $350.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 12th. Finally, Leerink Partners set a $330.00 price objective on shares of Natera in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Natera has a consensus rating of "Moderate Buy" and a consensus price target of $319.38.

Insider Activity at Natera

In other Natera news, CFO Michael Burkes Brophy sold 478 shares of the firm's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $274.22, for a total transaction of $131,077.16. Following the completion of the transaction, the chief financial officer directly owned 51,637 shares of the company's stock, valued at $14,159,898.14. This trade represents a 0.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 3,076 shares of the business's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $266.39, for a total transaction of $819,415.64. Following the completion of the sale, the chief executive officer directly owned 99,897 shares of the company's stock, valued at $26,611,561.83. The trade was a 2.99% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 184,472 shares of company stock valued at $42,799,604. Insiders own 5.05% of the company's stock.

Natera Stock Down 3.7%

NTRA stock opened at $326.26 on Friday. The stock's 50 day moving average is $285.07 and its two-hundred day moving average is $233.61. Natera, Inc. has a 52-week low of $157.43 and a 52-week high of $343.18. The company has a market capitalization of $47.03 billion, a PE ratio of -239.90 and a beta of 1.51.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. During the same period in the prior year, the business posted ($0.74) EPS. The business's revenue was up 37.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.02 EPS for the current year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source